Aelis Farma: Combined General Meeting of May 24, 2023: Availability of Preparatory Documents and Participation and Voting Procedures
03 5월 2023 - 1:00AM
Business Wire
Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME
eligible) (Paris: AELIS), a clinical-stage biopharmaceutical
company specialized in the development of treatments for brain
diseases, informs its shareholders and the financial community that
the Company’s Combined General Meeting will be held on
Wednesday, May 24, 2023, at 2 p.m., at 1 rue
Lafaurie de Mondabon, 33000 Bordeaux.
The notice of the meeting, including the agenda and draft
resolutions as well as the terms and conditions of participation
and voting at the meeting, was posted on the website of the
Bulletin des Annonces Légales Obligatoires "BALO" on April 17, 2023
(bulletin number 46).
Shareholders who are unable to attend the meeting in person, may
exercise their voting rights remotely, before the general
meeting:
- either by sending a proxy to the Company,
- or by voting by mail,
At this purpose, shareholders shall use the form available on
www.aelisfarma.com in accordance with the procedures indicated in
the notice of meeting published on April 17, 2023, in the BALO.
All documents relating to this General Meeting are available on
request from the Company or can be consulted on the Company's
website under the heading Investors / General Meetings.
In accordance with the applicable legal and regulatory
provisions:
- any registered shareholder may, up to and including the fifth
day before the general meeting, request that the Company send him
the documents provided for in Articles L. 225-115 and R. 225-83 of
the Commercial Code. In the event of an express request, such
documents may be sent by electronic means. For holders of bearer
shares, the exercise of this right is subject to the provision by
their authorized intermediary of a certificate of account
registration;
- any shareholder may consult the documents referred to in
Articles L. 225-115 and R. 225-83 of the Commercial Code at the
company's registered office.
***
About AELIS FARMA
Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical
company that is developing a new class of drugs, the Signaling
Specific inhibitors of the CB1 receptor of the endocannabinoid
system (CB1-SSi). CB1-SSi have been developed by Aelis Farma based
on the discovery of a new natural brain defense mechanism by the
team led by Dr. Pier Vincenzo Piazza, the Company’s CEO, when he
was Director of the INSERM Magendie Neurocenter in Bordeaux. By
reproducing this natural mechanism, CB1-SSi appear to be capable of
selectively inhibiting the disease-related activity of the CB1
receptor without disrupting its normal physiological activity. They
thus have significant potential for the treatment of numerous brain
diseases.
Aelis Farma is developing two first-in-class clinical-stage drug
candidates: AEF0117 for the treatment of disorders due to excessive
cannabis use, currently in a phase 2b study in the United States;
and AEF0217 for cognitive disorders, including those of Down
Syndrome (Trisomy 21), currently in a phase 1/2 study in Spain. The
Company also has a portfolio of innovative CB1-SSi for the
treatment of other disorders associated with a dysregulation of the
activity of the CB1 receptor.
Aelis Farma draws on the talents of more than 20 highly
qualified employees.
For more information, visit www.aelisfarma.com and follow
us on LinkedIn and Twitter.
ISIN: FR0014007ZB4 Ticker: AELIS B Compartment
of Euronext Paris
Disclaimer
Forward-looking statements
Some information contained in this press release are
forward-looking statements, not historical data. These
forward-looking statements are based on current beliefs,
expectations, and assumptions, including, but not limited to,
assumptions about Aelis Farma's current and future strategy and the
environment in which Aelis Farma operates. They involve known and
unknown risks, uncertainties, and other factors, which may cause
actual results, performance, or achievements, or industry results
or other events, to differ materially from those described or
implied by such forward-looking statements. These risks and
uncertainties include those set out and described in detail in
Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration
Document approved by the Autorité des Marchés Financiers on April
26, 2023, under number R.23-018.
These forward-looking statements are made only as of the date of
this press release and Aelis Farma expressly disclaims any
obligation or undertaking to release any updates or corrections to
the forward-looking statements included in this press release to
reflect any change in expectations or events, conditions, or
circumstances on which any such forward-looking statement is based.
Forward-looking information and statements are not guarantees of
future performance and are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond Aelis Farma's control. Actual results could differ
materially from those described in, or implied or projected by,
forward-looking information and statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230502005855/en/
AELIS FARMA Pier Vincenzo Piazza CEO
contact@aelisfarma.com
NewCap Dusan Oresansky/Aurélie Manavarere Investor
Relations aelis@newcap.eu +33 1 44 71 94 92
NewCap Arthur Rouillé Media Relations aelis@newcap.fr +33
1 44 71 00 15
Aelis Farma (EU:AELIS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Aelis Farma (EU:AELIS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024